"Our 24/7 Wall St. price target for Procter & Gamble ( NYSE:PG | PG Price Prediction) is $163.50, implying a 14.95% upside from today's price. Procter & Gamble trades at $142.24 as of May 13, 2026, with a $330.7 billion market cap and a beta of 0.4. Our recommendation is buy, with 90% confidence. PG is a defensive cash machine trading well below recent highs, supported by analyst consensus and stable earnings power."
"Fundamentals don't justify the weakness. Q3 FY2026, filed April 24, 2026, delivered Core EPS of $1.59 against a $1.55 consensus, with revenue of $21.23 billion, up 7.4% YoY. Beauty grew 7% organic, and every segment posted growth. CEO Shailesh Jejurikar said the quarter showed "a solid acceleration in top-line results... broad-based growth across product categories and regions." That marks five consecutive earnings beats."
"The bull case is credible. Our model's bull scenario points to $174.78 by May 2027, a 22.87% total return. Drivers include the Portfolio, Supply Chain and Productivity Plan targeting up to 7,000 non-manufacturing role reductions by end of FY2027, plus a Supply Chain 3.0 program aimed at $1.5 billion in cost-of-goods-sold savings. Innovation in synthetic biology, premium Skin Care mix, and emerging-market penetration in India, MEA, and Greater China underpin the multi-year story."
"External analysts agree. Simply Wall St's DCF model pegs PG as 21.3% undervalued, citing a P/E of 21x versus a fair ratio of 24x. Jim Cramer recently flagged the stock as a hedge against economic slowdown given its valuation. The dividend, now at $1.0885 quarterly with a 3% yield, marks PG's 70th consecutive annual increase."
Procter & Gamble trades at $142.24 with a $330.7 billion market cap and a beta of 0.4. A $163.50 price target implies 14.95% upside, and the recommendation is buy with 90% confidence. The stock is down 7.84% over 12 months, slightly positive year to date, and about 14% below the 52-week high. Q3 FY2026 reported Core EPS of $1.59 versus a $1.55 consensus and revenue of $21.23 billion, up 7.4% year over year, with growth across segments and five consecutive earnings beats. The bull case targets $174.78 by May 2027, supported by workforce reductions, Supply Chain 3.0 cost savings, synthetic biology innovation, premium skin care mix, and emerging-market expansion. External valuation models indicate undervaluation, and the dividend has increased for 70 consecutive years.
#procter--gamble #stock-price-target #earnings-and-eps #cost-savings-and-supply-chain #dividend-growth
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]